Methods comprising continuous administration of a GLP-1 receptor agonist and co-administration of a drug
Provided is a method for administering to a subject, via an implantable delivery device, a continuous subcutaneous dose of glucagon-like peptide-1 (GLP-1) analog, where the subject is orally co-administered a drug after implantation of the implantable delivery device and during continuous subcutaneous dosing of the GLP-1 analog.
1. A method comprising administering to a subject in need thereof, via an implantable delivery device, a continuous subcutaneous dose of glucagon-like peptide-1 (GLP-1) analog, wherein the subject is orally co-administered a drug after implantation of the implantable delivery device and during continuous subcutaneous dosing of the GLP-1 analog, and wherein the drug is administered without dose adjustment for treatment of a disease or disorder other than type-2 diabetes.
2. The method of claim 1 , wherein the disease or disorder other than type-2 diabetes is selected from the group consisting of pain, elevated blood levels of cholesterol, heart disease, hypertension, heart attack, stroke or blood clot.
3. The method of claim 1 , wherein the drug is administered to prevent conception of a child.
4. The method of claim 1 , wherein the drug is selected from the group consisting of acetaminophen, atorvastatin, lisinopril, digoxin, ethinyl estradiol, and levonorgestrel, R-warfarin, and S-warfarin.
5. The method of claim 1 , wherein the drug is a pain reliever.
6. The method of claim 1 , wherein the drug is acetaminophen.
7. The method of claim 1 , wherein the drug is an oral contraceptive.
8. The method of claim 1 , wherein the drug is one or both of ethinyl estradiol and levonorgestrel.
9. The method of claim 1 , wherein the drug is for the treatment of elevated blood levels of cholesterol.
10. The method of claim 1 , wherein the drug is a statin.
11. The method of claim 1 , wherein the drug is atorvastatin.
12. The method of claim 1 , wherein the drug is for the treatment or prevention of hypertension and/or heart disease.
13. The method of claim 1 , wherein the drug is digoxin.
14. The method of claim 1 , wherein the drug is an angiotensin converting enzyme (ACE) inhibitor.
15. The method of claim 1 , wherein the drug is lisinopril.
16. The method of claim 1 , wherein the drug is for the treatment or prevention of a heart attack, stroke, hypertension or blood clot.
17. The method of claim 1 , wherein the drug is an anticoagulant.
18. The method of claim 1 , wherein the drug is R-warfarin and/or S-warfarin.
19. The method of claim 1 , wherein the drug is self-administered by the subject.
20. The method of claim 1 , wherein the GLP-1 analog is exenatide.
21. The method of claim 1 , wherein the GLP-1 analog is other than exenatide.
22. The method of claim 21 , wherein the GLP-1 analog is selected from the group consisting of OZEMPIC® (semaglutide), VICTOZA® (liraglutide), ADLYXIN® (lixisenatide); TENZEUM® (albiglutide) and TRULICITY® (dulaglutide).
23. The method of claim 1 , wherein the GLP-1 analog is administered for treatment of a metabolic disorder.
24. The method of claim 1 , wherein the GLP-1 analog is administered for treatment of a type 2 diabetes mellitus.
25. The method of claim 1 , wherein the GLP-1 analog is administered for treatment of obesity.
26. The method of claim 1 , wherein the GLP-1 analog is administered for effecting weight loss in the subject.
27. The method of claim 1 , wherein the subject is administered a dose of 20 μg/day exenatide.
28. The method of claim 1 , wherein the subject is administered a dose of 60 μg/day exenatide.
29. The method of claim 1 , wherein the subject is human.